drugset / Trial / NCT02099461

Effect of Denosumab on Cellular Biomarkers in the Human Breast

NCT02099461

Phase 1 Completed 82 enrolled Amgen
RandomizedParallel-groupOpen-labelBasic science

Summary

To evaluate whether administration of denosumab results in a decrease compared to the control group in proliferation of mammary epithelial cells as measured by the Ki-67 proliferation index.

Timeline

Start
2014-04
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Denosumab Monoclonal antibody 60 mg Subcutaneous
Subject Denosumab Monoclonal antibody 120 mg Subcutaneous

Indications

No indication recorded.